Extended dosing intervals enhance the durability of a self-amplifying mRNA vaccine against pandemic H5N1 influenza: a randomized, observer-blind, dose-finding Phase I study

Antoinette A. Pragalos, Filippo Pacciarini, Hongfan Jin, Terri Hopkins, Ye Zhang, Roberto Bugarini, Xuexuan Liu, Brian M. Sullivan, Carole Verhoeven, Igor Smolenov

Open source

DOI
10.1038/s41467-026-78031-9
Published
2026-09-24
Container
Nature Communications
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41467-026-78031-9,
  title = {Extended dosing intervals enhance the durability of a self-amplifying mRNA vaccine against pandemic H5N1 influenza: a randomized, observer-blind, dose-finding Phase I study},
  author = {Antoinette A. Pragalos and Filippo Pacciarini and Hongfan Jin and Terri Hopkins and Ye Zhang and Roberto Bugarini and Xuexuan Liu and Brian M. Sullivan and Carole Verhoeven and Igor Smolenov},
  year = {2026},
  journal = {Nature Communications},
  doi = {10.1038/s41467-026-78031-9},
  url = {https://doi.org/10.1038/s41467-026-78031-9}
}

RIS

TY  - JOUR
TI  - Extended dosing intervals enhance the durability of a self-amplifying mRNA vaccine against pandemic H5N1 influenza: a randomized, observer-blind, dose-finding Phase I study
AU  - Antoinette A. Pragalos
AU  - Filippo Pacciarini
AU  - Hongfan Jin
AU  - Terri Hopkins
AU  - Ye Zhang
AU  - Roberto Bugarini
AU  - Xuexuan Liu
AU  - Brian M. Sullivan
AU  - Carole Verhoeven
AU  - Igor Smolenov
PY  - 2026
JO  - Nature Communications
DO  - 10.1038/s41467-026-78031-9
UR  - https://doi.org/10.1038/s41467-026-78031-9
ER  - 

APA

Pragalos, A. A., Pacciarini, F., Jin, H., Hopkins, T., Zhang, Y., Bugarini, R., Liu, X., Sullivan, B. M., Verhoeven, C., & Smolenov, I. (2026). Extended dosing intervals enhance the durability of a self-amplifying mRNA vaccine against pandemic H5N1 influenza: a randomized, observer-blind, dose-finding Phase I study. Nature Communications. https://doi.org/10.1038/s41467-026-78031-9

Source records